Bogdan J Wlodarczyk1, Huiping Zhu2, Richard H Finnell2. 1. Center for Environmental and Genetic Medicine, Institute of Biosciences and Technology, Texas A&M University System Health Science Center, 2121 West Holcombe Blvd., Houston, TX 77030, USA. Electronic address: bwlodarczyk@austin.utexas.edu. 2. Center for Environmental and Genetic Medicine, Institute of Biosciences and Technology, Texas A&M University System Health Science Center, 2121 West Holcombe Blvd., Houston, TX 77030, USA.
Abstract
BACKGROUND: In utero exposure to arsenic is known to adversely affect reproductive outcomes. Evidence of arsenic teratogenicity varies widely and depends on individual genotypic differences in sensitivity to As. In this study, we investigated the potential interaction between 5,10-methylenetetrahydrofolate reductase (Mthfr) genotype and arsenic embryotoxicity using the Mthfr knockout mouse model. METHODS: Pregnant dams were treated with sodium arsenate, and reproductive outcomes including: implantation, resorption, congenital malformation and fetal birth weight were recorded at E18.5. RESULTS: When the dams in Mthfr(+/-)×Mthfr(+/-) matings were treated with 7.2 mg/kg As, the resorption rate increased to 43.4%, from a background frequency of 7.2%. The As treatment also induced external malformations (40.9%) and significantly lowered the average fetal birth weight among fetuses, without any obvious toxic effect on the dam. When comparing the pregnancy outcomes resulting from different mating scenarios (Mthfr(+/+)×Mthfr(+/-), Mthfr(+/-)×Mthfr(+/-) and Mthfr(-/-)×(Mthfr+/-)) and arsenic exposure; the resorption rate showed a linear relationship with the number of null alleles (0, 1 or 2) in the Mthfr dams. Fetuses from nullizygous dams had the highest rate of external malformations (43%) and lowest average birth weight. When comparing the outcomes of reciprocal matings (nullizygote×wild-type versus wild-type×nullizygote) after As treatment, the null dams showed significantly higher rates of resorptions and malformations, along with lower fetal birth weights. CONCLUSIONS: Maternal genotype contributes to the sensitivity of As embryotoxicity in the Mthfr mouse model. The fetal genotype, however, does not appear to affect the reproductive outcome after in utero As exposure. Published by Elsevier Inc.
BACKGROUND: In utero exposure to arsenic is known to adversely affect reproductive outcomes. Evidence of arsenic teratogenicity varies widely and depends on individual genotypic differences in sensitivity to As. In this study, we investigated the potential interaction between 5,10-methylenetetrahydrofolate reductase (Mthfr) genotype and arsenic embryotoxicity using the Mthfr knockout mouse model. METHODS: Pregnant dams were treated with sodium arsenate, and reproductive outcomes including: implantation, resorption, congenital malformation and fetal birth weight were recorded at E18.5. RESULTS: When the dams in Mthfr(+/-)×Mthfr(+/-) matings were treated with 7.2 mg/kg As, the resorption rate increased to 43.4%, from a background frequency of 7.2%. The As treatment also induced external malformations (40.9%) and significantly lowered the average fetal birth weight among fetuses, without any obvious toxic effect on the dam. When comparing the pregnancy outcomes resulting from different mating scenarios (Mthfr(+/+)×Mthfr(+/-), Mthfr(+/-)×Mthfr(+/-) and Mthfr(-/-)×(Mthfr+/-)) and arsenic exposure; the resorption rate showed a linear relationship with the number of null alleles (0, 1 or 2) in the Mthfr dams. Fetuses from nullizygous dams had the highest rate of external malformations (43%) and lowest average birth weight. When comparing the outcomes of reciprocal matings (nullizygote×wild-type versus wild-type×nullizygote) after As treatment, the null dams showed significantly higher rates of resorptions and malformations, along with lower fetal birth weights. CONCLUSIONS: Maternal genotype contributes to the sensitivity of As embryotoxicity in the Mthfrmouse model. The fetal genotype, however, does not appear to affect the reproductive outcome after in utero As exposure. Published by Elsevier Inc.
Authors: Eoin P Quinlivan; Steven R Davis; Karla P Shelnutt; George N Henderson; Haifa Ghandour; Barry Shane; Jacob Selhub; Lynn B Bailey; Peter W Stacpoole; Jesse F Gregory Journal: J Nutr Date: 2005-03 Impact factor: 4.798
Authors: Z Chen; A C Karaplis; S L Ackerman; I P Pogribny; S Melnyk; S Lussier-Cacan; M F Chen; A Pai; S W John; R S Smith; T Bottiglieri; P Bagley; J Selhub; M A Rudnicki; S J James; R Rozen Journal: Hum Mol Genet Date: 2001-03-01 Impact factor: 6.150
Authors: P F Jacques; A G Bostom; R R Williams; R C Ellison; J H Eckfeldt; I H Rosenberg; J Selhub; R Rozen Journal: Circulation Date: 1996-01-01 Impact factor: 29.690
Authors: Sajin Bae; Elena Kamynina; Heather M Guetterman; Adetutu F Farinola; Marie A Caudill; Robert J Berry; Patricia A Cassano; Patrick J Stover Journal: Cochrane Database Syst Rev Date: 2021-10-18
Authors: Maitreyi Mazumdar; Linda Valeri; Ema G Rodrigues; Md Omar Sharif Ibne Hasan; Rezina Hamid; Ligi Paul; Jacob Selhub; Fareesa Silva; Md Golam Mostofa; Quazi Quamruzzaman; Mahmuder Rahman; David C Christiani Journal: Birth Defects Res A Clin Mol Teratol Date: 2015-08-06
Authors: Donato F Romagnolo; Kevin D Daniels; Jonathan T Grunwald; Stephan A Ramos; Catherine R Propper; Ornella I Selmin Journal: Mol Nutr Food Res Date: 2016-06 Impact factor: 5.914
Authors: Maitreyi Mazumdar; Md Omar Sharif Ibne Hasan; Rezina Hamid; Linda Valeri; Ligi Paul; Jacob Selhub; Ema G Rodrigues; Fareesa Silva; Selim Mia; Md Golam Mostofa; Quazi Quamruzzaman; Mahmuder Rahman; David C Christiani Journal: Environ Health Date: 2015-04-10 Impact factor: 5.984